CureVac Enters the Market With a Bang

By Chris Lange Published Aug 14, 1:38PM EDT

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

CureVac Enters the Market With a Bang — © Thinkstock

CureVac B.V. (NASDAQ: CVAC) wasn’t the only initial public offering making some noise in the markets on Friday, but the stock exploded into the market, more than double its original pricing. Since then, it is up more or less triple its original pricing.

The company priced its 13.33 million shares at $16, at the high end of the expected price range of $14 to $16. There is an overallotment option for an additional 2.00 million shares. At this price, the entire offering is valued up to $245.28 million.

The underwriters for the offering are BofA Securities, Jefferies, Credit Suisse, Berenberg and Kempen.

CureVac is a global clinical-stage biopharmaceutical company in the field of messenger RNA (mRNA) technology with expertise in developing and optimizing this versatile molecule for medical purposes. However, the most exciting part of its pipeline is its COVID-19 vaccine.

[nativounit]

The principle of CureVac’s proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of prophylactic vaccines, cancer therapies, antibody therapies and the treatment of protein therapies.

The company intends to use the net proceeds from this offering and a concurrent private placement offering to further develop and commercialize its SARS-CoV-2 vaccine program. The proceeds also will be used to develop other facets of its pipeline and for working capital and general corporate purposes.

CureVac stock was last seen up about 211% at $49.85, in a range of $36.15 to $51.48 on the day thus far. About 12 million shares had moved as of 1:15 p.m. Eastern.

[recirclink id=729110][wallst_email_signup]

About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.